Arecor Therapeutics PLC (GB:AREC) has released an update.
Arecor Therapeutics PLC has announced a collaboration with Medtronic Diabetes to create a new thermostable insulin for next-generation implantable pumps, targeting patients with limited traditional therapy options and aiming to reduce the frequency of pump maintenance. This partnership aligns with Arecor’s innovative product development, including their ultra-rapid acting insulins AT278 and AT247, and adds to their expansive diabetes management portfolio. The new insulin aims to simplify treatment, enhance physician utility, and provide cost savings in healthcare.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.
